115 related articles for article (PubMed ID: 37357945)
1. Prognostic significance of pre-treatment albumin-bilirubin grade in metastatic urothelial carcinoma receiving pembrolizumab.
Yamashita S; Wada T; Deguchi R; Mashima N; Higuchi M; Miyai H; Koike H; Kohjimoto Y; Hara I
Jpn J Clin Oncol; 2023 Aug; 53(9):845-850. PubMed ID: 37357945
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the albumin-bilirubin grade as a prognostic factor in patients with non-small-cell lung cancer receiving anti-PD-1-based therapy.
Takada K; Takamori S; Shimokawa M; Toyokawa G; Shimamatsu S; Hirai F; Tagawa T; Okamoto T; Hamatake M; Tsuchiya-Kawano Y; Otsubo K; Inoue K; Yoneshima Y; Tanaka K; Okamoto I; Nakanishi Y; Mori M
ESMO Open; 2022 Feb; 7(1):100348. PubMed ID: 34942439
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy.
Matsukane R; Watanabe H; Hata K; Suetsugu K; Tsuji T; Egashira N; Nakanishi Y; Okamoto I; Ieiri I
Sci Rep; 2021 Jul; 11(1):15057. PubMed ID: 34301991
[TBL] [Abstract][Full Text] [Related]
4. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
5. Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
Brown JT; Liu Y; Shabto JM; Martini DJ; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni LB; Joshi SS; Kissick H; Ogan K; Harris WB; Carthon BC; Kucuk O; Master VA; Bilen MA
Oncologist; 2021 May; 26(5):397-405. PubMed ID: 33634507
[TBL] [Abstract][Full Text] [Related]
6. FAN score comprising fibrosis-4 index, albumin-bilirubin score and neutrophil-lymphocyte ratio is a prognostic marker of urothelial carcinoma patients treated with pembrolizumab.
Kawashima A; Yamamoto Y; Sato M; Nakata W; Kakuta Y; Ishizuya Y; Yamaguchi Y; Yamamoto A; Yoshida T; Takayama H; Takada T; Inoue H; Okuda Y; Kato T; Hatano K; Uemura M; Nonomura N; Imamura R
Sci Rep; 2021 Oct; 11(1):21199. PubMed ID: 34707147
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A;
Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178
[TBL] [Abstract][Full Text] [Related]
8. The Relationship between albumin-Bilirubin grade and survival in hepatocelluler carcinoma patients treated with sorefanib.
Fidan E; Fidan S; Merev E; Kazaz N
Niger J Clin Pract; 2022 Feb; 25(2):173-177. PubMed ID: 35170443
[TBL] [Abstract][Full Text] [Related]
9. Low Geriatric Nutritional Risk Index as a Poor Prognostic Marker for Second-Line Pembrolizumab Treatment in Patients with Metastatic Urothelial Carcinoma: A Retrospective Multicenter Analysis.
Etani T; Naiki T; Sugiyama Y; Nagai T; Iida K; Noda Y; Shimizu N; Tasaki Y; Mimura Y; Okada T; Banno R; Kubota H; Hamamoto S; Ando R; Kawai N; Yasui T
Oncology; 2020; 98(12):876-883. PubMed ID: 32862183
[TBL] [Abstract][Full Text] [Related]
10. The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A Real-World Study.
Hatanaka T; Naganuma A; Shibasaki M; Kohga T; Arai Y; Nagashima T; Ueno T; Namikawa M; Saito S; Hoshino T; Takizawa D; Arai H; Makita F; Kakizaki S; Harimoto N; Shirabe K; Uraoka T
Oncology; 2021; 99(4):203-214. PubMed ID: 33279908
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of the albumin-to-globulin ratio for advanced urothelial carcinoma treated with pembrolizumab: a multicenter retrospective study.
Taguchi S; Kawai T; Nakagawa T; Nakamura Y; Kamei J; Obinata D; Yamaguchi K; Kaneko T; Kakutani S; Tokunaga M; Uemura Y; Sato Y; Fujimura T; Fukuhara H; Enomoto Y; Nishimatsu H; Takahashi S; Kume H
Sci Rep; 2021 Aug; 11(1):15623. PubMed ID: 34341416
[TBL] [Abstract][Full Text] [Related]
12. Modified Glasgow prognostic score is a pre-surgical prognostic marker of disease mortality in upper urinary tract urothelial carcinoma.
Tsuzuki S; Kimura S; Fukuokaya W; Yanagisawa T; Hata K; Miki J; Kimura T; Abe H; Egawa S
Jpn J Clin Oncol; 2021 Jan; 51(1):138-144. PubMed ID: 32728722
[TBL] [Abstract][Full Text] [Related]
13. Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA study.
Tanabe K; Kobayashi S; Maezawa Y; Ishihara K; Inoue N; Izumi K; Fujiwara M; Toide M; Yamamoto T; Uehara S; Araki S; Inoue M; Takazawa R; Numao N; Ohtsuka Y; Tanaka H; Yoshida S; Fujii Y
Int J Clin Oncol; 2024 Jun; ():. PubMed ID: 38833113
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of albumin-bilirubin score in patients with unresectable hepatocellular carcinoma undergoing combined immunotherapy and radiotherapy.
Dong D; Zhu X; Wang H; Li L; Wan M; Li S; Zhang Y; Geng J; Li Y; Wang W
J Med Imaging Radiat Oncol; 2022 Aug; 66(5):662-670. PubMed ID: 35243796
[TBL] [Abstract][Full Text] [Related]
15. Effects of Proton Pump Inhibitors on Survival Outcomes in Patients with Metastatic or Unresectable Urothelial Carcinoma Treated with Pembrolizumab.
Kunimitsu Y; Morio K; Hirata S; Yamamoto K; Omura T; Hara T; Harada K; Fujisawa M; Yano I
Biol Pharm Bull; 2022; 45(5):590-595. PubMed ID: 35491164
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Baseline ALBI Score Among Patients With Colorectal Liver Metastases: A Pooled Analysis of Two Randomized Trials.
Abdel-Rahman O
Clin Colorectal Cancer; 2019 Mar; 18(1):e61-e68. PubMed ID: 30348618
[TBL] [Abstract][Full Text] [Related]
17. The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients.
Ogihara K; Kikuchi E; Shigeta K; Okabe T; Hattori S; Yamashita R; Yoshimine S; Shirotake S; Nakazawa R; Matsumoto K; Mizuno R; Hara S; Oyama M; Masuda T; Niwakawa M; Oya M
Urol Oncol; 2020 Jun; 38(6):602.e1-602.e10. PubMed ID: 32139290
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.
Narayan V; Kahlmeyer A; Dahm P; Skoetz N; Risk MC; Bongiorno C; Patel N; Hwang EC; Jung JH; Gartlehner G; Kunath F
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012838. PubMed ID: 30036453
[TBL] [Abstract][Full Text] [Related]
19. Significant Improvement of Prognosis After the Advent of Immune Checkpoint Inhibitors in Patients with Advanced, Unresectable, or Metastatic Urothelial Carcinoma: A Propensity Score Matching and Inverse Probability of Treatment Weighting Analysis on Real-World Data.
Miyake M; Nishimura N; Shimizu T; Ohnishi M; Kuwada M; Itami Y; Inoue T; Ohnishi K; Matsumoto Y; Yoshida T; Tatsumi Y; Shinohara M; Hori S; Morizawa Y; Gotoh D; Nakai Y; Anai S; Torimoto K; Aoki K; Fujii T; Tanaka N; Fujimoto K
Cancer Manag Res; 2022; 14():623-635. PubMed ID: 35210859
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety profile of pembrolizumab for metastatic urothelial cancer: A retrospective single-center analysis in Japan.
Fujiwara M; Yuasa T; Urasaki T; Komai Y; Fujiwara R; Numao N; Yamamoto S; Yonese J
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1398. PubMed ID: 33934570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
